2013

Description Through its family of companies, the worlds most comprehensive and

broadly based manufacturer of health care products Serves the Consumer, Pharmaceutical and Medical Devices and

Diagnostics markets by developing broadly accessible, high quality, innovative products and services that advance the health and well-being of people

Consistent Performance 30 consecutive years of earnings increases adjusted for special items 51 consecutive years of dividends increases

One Year2 Five Years2 Ten Years2 Sales 6.1% 2.3% 5.5% Diluted Adjusted Earnings per Share 1

8.2% 3.9% 8.1%

Dividend Growth 7.9% 7.6% 10.8% Total Return to Shareholders 34.6% 12.6% 8.9% 1 Non-GAAP, excludes special items. Reconciliation available in corresponding Annual Reports. 2 Compounded Annual Growth Rates Broadly Based/Exceptional Financial Strength Over 275 operating companies in 60 countries selling products

throughout the world (approximately 55% of sales outside of U.S.) Sales split among Consumer, Pharmaceutical and Medical Devices and

Diagnostics business segments More than 100 drugs marketed; 41 drugs over $50 million; 32 drugs over

$100 million; 8 drugs over $1 billion One of four U.S. industrial companies that still commands a Triple A

credit rating by both Standard & Poors and Moodys credit rating agencies

Generated annual free cash flow1 in 2013 of $13.8 billion. 1Non-GAAP financial measure; defined as operating cash flow less capital spending

(1) Net Earnings attributable to Johnson & Johnson

Worldwide Market Leadership Largest Medical Device company 7th largest Pharmaceutical company

globally 6th largest Biotech company globally 6th largest Consumer Health Care

company globally Leadership Positions in Major Markets:

Antithrombotic agents Antipsychotics (Injectables) Anti - TNF Baby Care Biosurgicals Blood Glucose Monitoring Breast Aesthetics Disposable Contact Lenses Electrophysiology diagnostics

& catheters Hormone antagonists Infection Prevention Lo-Cal Sweeteners Minimally Invasive Surgery Oral Rinses Orthopaedics OTC Analgesics Sanitary Protection Sutures Systemic Antipsoriasis

products Wound Care

Approximately 70% of sales are derived from products/businesses that have a #1 or #2 global market share position

2013 Worldwide Sales $71.3 Billion

2013 Investor Fact Sheet

Approximately ##%

Please visit our Home Page on the Internet at http://www.jnj.com for requests for Company Reports, including the 2013 Annual Report and SEC filings. Questions regarding stock holdings and the Dividend Reinvestment Plan, should be directed to: Computershare Trust Company,N.A. Phone (800) 328-9033

2003

$6,848

2008

Net Earnings(1) (as reported) $U.S. Millions $12,949

$13,831

Approximately 25%

New Products Introduced in Past 5 Years

21

Strong Commitment to New Product Development $8.2 billion in Research &

Development expense in 2013 Numerous external alliances and

collaborations entered into annually

Approximately 25% of products sold in 2013 introduced in last 5 years

Management Based on a Core Set of Strategic Principles Creating Value through Innovation

o Robust pipeline of new and innovative products

Global Reach/Local Focus o Broad geographic reach

provides ability to rapidly introduce new products in markets around the world

Excellence in Execution o Maintaining high quality

products and standards Leading with a Purpose

o Focus on products which increase access, reduce cost and improve the quality of health care

Investor Information NYSE Symbol: JNJ For additional information, contact: Investor Relations Department One Johnson & Johnson Plaza New Brunswick, NJ 08933 Voice: (800) 950-5089 Fax: (732) 524-3867 Press releases, including earnings reports, are available via web access: http://www.jnj.com

$18.6

$7.4$13.4

$31.9

80105130155180205230

2003 2005 2007 2009 2011 2013

DO

LLA

RS

Johnson & JohnsonS&P 500S&P PharmS&P H/C Equip

2013 Sales by Geographic Area $U.S. Billions

Shareholder Return Comparison $100 Dollars invested December 31, 2003

This chart provides a comparison of cumulative total shareholder return for an investment in Johnson & Johnson Common Stock as of December 31, 2013 to a similar investment in the identified indices. Assuming dividends were reinvested, a $100.00 investment in Johnson & Johnson would have grown to $235.59 as of December 31, 2013. This compares to a value of $204.26 for the S&P 500 Stock Index, $193.25 for the S&P Pharmaceutical Index and $166.10 for the S&P Healthcare Equipment Index. Source: Bloomberg

Europe

U.S.

Western Hemisphere

Asia-Pacific Africa

45%

26%

10%

19%

$28.5

$28.1

$14.7

2013 Sales by Segment $U.S. Billions

21% 40%

39%

MD&D

Pharmaceutical

Consumer

InternationalU.S.

Net Trade Sales $U.S. Billions

2003 2008 2013

Johnson & Johnson 2013

$71.3

$63.7

$41.9

22

Cover Sheet testPg 01 Indexpg 02 2013 5 Yr Select Fin Data5yr Select Data

Pg 03 Consumer,MDD and Pharm V2pg 04 2013 Balance Sheet2013-2011 book formats

pg 05 2013 Statement of EarningsStmt of Earnings2

pg 06 2013 Cash Flow10K

pg 07-08 2013 Segmentspage 7-8

pg 09 2013 Geographic Areaspage 9

pg 10 2013 Sales Growth RatesSales Growh Rates

pg 11-12 2013 Quarterly Sales by Segmentpage 11-12

pg 13-14 2013 Quarterly Income StatementNet Income

pg 15 1888-2013 NTS NIrestated

pg 16-18 2013 Stock InfoSplit & Repurch Pg 16Stock Pg 17-18

Pg 19 Non GAAP Reconciliation 13non-gaap info for 5 Year Book

Pg 20 Final PagePg 21 2013 Investor Fact SheetDescriptionConsistent PerformanceFive Years2SalesDividend Growth

Broadly Based/Exceptional Financial Strength

Pg 22 2013 Investor Fact Sheet back page